Definium Therapeutics (DFTX) Non-Current Assets (2020 - 2026)

Definium Therapeutics (DFTX) has 7 years of Non-Current Assets data on file, last reported at $20.7 million in Q1 2026.

• Quarterly Non-Current Assets fell 61.34% year-over-year to $20.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.5 million (up 20.45% YoY) and the FY2025 annual result came in at $20.8 million, up 1.21% from the prior year.
• Non-Current Assets steadied at $20.7 million in Q1 2026 per DFTX's latest filing, from $20.8 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $76.0 million in Q2 2025 and bottomed at $20.1 million in Q1 2024.
• The 5-year median for Non-Current Assets is $21.5 million (2023), against an average of $27.1 million.
• The widest annual swing landed in 2025, when Non-Current Assets soared 271.38%; it then slumped 61.34% in 2026.
• Tracing DFTX's Non-Current Assets over 5 years: stood at $23.9 million in 2022, then retreated by 13.66% to $20.7 million in 2023, then decreased by 0.67% to $20.5 million in 2024, then climbed by 1.21% to $20.8 million in 2025, then slipped by 0.24% to $20.7 million in 2026.
• Per Business Quant, the three latest DFTX Non-Current Assets figures stand at $20.7 million (Q1 2026), $20.8 million (Q4 2025), and $21.1 million (Q3 2025).

Peer Comparison